FocalTherics (NASDAQ:FOCL) Director Buys 10,000 Shares

Key Points

• Director Joshua Levine purchased 10,000 FocalTherics shares at an average price of $4.75, investing $47,500 and increasing his ownership by 28.57% to 45,000 shares.
• FocalTherics reported a quarterly loss of $0.39 per share, missing the consensus estimate of a $0.20 loss, on revenue of $13.20 million. Analysts expect a full-year loss of $0.78 per share.
• Analyst views are mixed, resulting in a consensus “Hold” rating and a $7.75 average price target; the stock recently opened at $4.76, compared with a 52-week range of $1.30 to $6.40.

FocalTherics (NASDAQ:FOCL - Get Free Report) Director Joshua Levine purchased 10,000 shares of the stock in a transaction on Friday, August 14th. The shares were bought at an average price of $4.75 per share, for a total transaction of $47,500.00. Following the acquisition, the director owned 45,000 shares of the company's stock, valued at approximately $213,750. The trade was a 28.57% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

FocalTherics Price Performance

Shares of FOCL opened at $4.76 on Monday. The company has a market cap of $178.40 million, a P/E ratio of -4.62 and a beta of -0.04. The stock has a fifty day moving average price of $5.39. FocalTherics has a one year low of $1.30 and a one year high of $6.40. The company has a quick ratio of 0.99, a current ratio of 1.34 and a debt-to-equity ratio of 1.79.

FocalTherics (NASDAQ:FOCL - Get Free Report) last announced its earnings results on Friday, August 14th. The company reported ($0.39) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.19). The business had revenue of $13.20 million for the quarter. FocalTherics had a negative net margin of 56.26% and a negative return on equity of 175.45%. Analysts anticipate that FocalTherics will post -0.78 earnings per share for the current year.

Analysts Set New Price Targets

A number of analysts recently weighed in on FOCL shares. HC Wainwright reissued a "buy" rating and issued a $10.00 target price on shares of FocalTherics in a research note on Tuesday, June 2nd. Mizuho set a $15.00 price target on FocalTherics and gave the company an "outperform" rating in a report on Friday, July 17th. Piper Sandler restated a "neutral" rating and issued a $4.00 price objective on shares of FocalTherics in a research report on Friday. Finally, Wall Street Zen downgraded shares of FocalTherics from a "hold" rating to a "sell" rating in a research report on Saturday. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus price target of $7.75.

Institutional Investors Weigh In On FocalTherics

A number of institutional investors have recently made changes to their positions in the company. SmartHarvest Portfolios LLC acquired a new position in FocalTherics in the 1st quarter valued at $38,000. Lido Advisors LLC acquired a new position in shares of FocalTherics in the 1st quarter valued at approximately $40,000. Kovack Advisors Inc. bought a new stake in shares of FocalTherics during the 4th quarter worth approximately $53,000. Leonteq Securities AG bought a new stake in shares of FocalTherics during the 4th quarter worth approximately $313,000. Finally, Flax Pond Capital LLC acquired a new stake in shares of FocalTherics during the 4th quarter worth approximately $2,623,000. Institutional investors own 62.74% of the company's stock.

About FocalTherics

EDAP TMS SA, together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. It operates in three segments: High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST). The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source